Welcome to Evivo

Evivo is the only clinically proven baby probiotic of its kind. Evivo contains the good bacteria B. infantis, which fully utilizes breast milk to protect baby's gut from potentially harmful bacteria linked to a higher risk of colic, eczema, allergies, diabetes, and obesity.

 

Landmark Results Recently Published

Evivo Proven to Restore Baby Gut Microbiome to Natural and Protective State

Pediatrician with Evivo baby

12/6/2017 — The bacteria in Evivo, Bifidobacterium longum subsp. infantis (B. infantis) is the critically important bacteria in baby’s gut microbiome early in life. It helps to program metabolism and the immune system and supports the complete digestion of nutrients.

Unfortunately, due to generations of modern medical practices such as antibiotics and C-sections, most babies no longer acquire B. infantis  early in life. Without it, potentially harmful bacteria thrive which have been linked to higher risk of colic, eczema, allergies, diabetes, and obesity. To date, probiotics have focused on general gut health and digestion, but until now had not demonstrated the ability to reduce potentially harmful bacteria.

In a controlled clinical trial led by University of California, Davis Medical Center, breastfed babies were given Evivo (activated B. infantis EVC001) once a day and compared to a similar group of babies who did not receive Evivo.  This study showed the first-ever restoration of the baby gut microbiome via Evivo. Babies given Evivo saw a 79% increase in bifidobacteria. These Evivo babies also experienced an unprecedented 80% reduction of groups of potentially harmful bacteria such as E. coli, clostridia, Staphylococcus (Staph), and Streptococcus (Strep), which have been linked to disease later in life.  Finally, across all babies in the study, those high in bifidobacteria had four times lower levels of endotoxin, a compound known to cause inflammation.

In summary, providing Evivo to babies in this clinical study completely restored the naturally protective gut microbiome in 100% of breastfed babies and significantly reduced potentially harmful groups of bacteria compared to babies who didn’t receive Evivo.

To read this article in full:     

LEARN MORE

Safety & Tolerability Summary

Increasing levels of the key beneficial bacteria, Bifidobacterium, in baby’s gut

5/30/2017 — One key beneficial bacteria is designed by nature to live in babies’ gut, and thrive in the presence of human breast milk: Bifidobacterium (including B. infantis). In fact, the higher the levels of Bifidobacterium in baby’s gut early in life reduces the amount of potentially harmful bacteria which are linked later in life to a higher risk of many conditions like colic, eczema, allergies, diabetes, and obesity. In this recent clinical trial led by The University of California, breast fed babies were given Evivo (activated B. infantis) once a day for a month and were compared to breast fedbabies who didn’t receive any probiotic. After a month, Evivo babies had significantly higher levels of total Bifidobacterium in their gut compared to babies who didn’t receive Evivo. This once-daily probiotic is clinically proven to restore Bifidobacterium to baby’s gut and reduce the amount of potentially harmful bacteria. It’s the first and only baby probiotic of its kind to help establish the foundation of lifelong well-being.

Background: Historically, bifidobacteria were the dominant intestinal bacteria in breastfed infants. Still abundant in infants in developing nations, levels of intestinal bifidobacteria are low among infants in developed nations. Recent
studies have described an intimate relationship between human milk and a specific subspecies of Bifidobacterium, B. longum subsp. infantis (B. infantis), yet supplementation of breastfed, healthy, term infants with this organism, has not been reported. The IMPRINT Study, a Phase I clinical trial, was initiated to determine the safety and tolerability of supplementing breastfed infants with B. infantis (EVC001).

Methods: Eighty mother-infant dyads were enrolled in either lactation support plus B. infantis supplementation (BiLS) or lactation support alone (LS). Starting with Day 7 postnatal, BiLS infants were fed 1.8–2.8 × 1010 CFU B. infantis EVC001 daily in breast milk for 21 days. Mothers collected fecal samples, filled out health questionnaires, and kept daily logs about their infants’ feeding and gastrointestinal symptoms from birth until Day 61 postnatal.
Safety and tolerability were determined from maternal reports.

Results: There were no differences in the mean gestational age at birth, weight 1 and 2 months postnatal, and breast milk intake between groups. The mean Log10 change in fecal Bifidobacterium from Day 6 to Day 28 was higher (p = 0.0002) for BiLS (6.6 ± 2.8 SD) than for LS infants (3.5 ± 3.5 SD). Daily stool number was higher (p < 0.005) for LS and lower (p < 0.05) for BiLS infants during supplementation than at Baseline. During supplementation, watery stools decreased and soft stools increased by 36% over baseline in BiLS infants (p < 0.05) with no significant changes in stool consistency for the LS infants. None of the safety and tolerability endpoints, including flatulence, bloody stool, body temperature, ratings of gastrointestinal symptoms, use of antibiotics or gas-relieving medications, infant colic, jaundice, number of illnesses, sick doctor visits, or diagnoses of eczema were different for the groups at any point. Conclusions: The B. infantis EVC001 supplement was safely consumed and well-tolerated. Stools were fewer and better formed in infants in the BiLS group compared with LS group. Adverse events were those expected in healthy infants and not different between groups.

To read this article in full:    

LEARN MORE